clinical trial · NCT07545226
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.
Healthy ParticipantsEvolocumab Drug Substance A (Test)Evolocumab Drug Substance B (Reference)
brief summary
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.
started
Apr 21, 2026
primary completion
Sep 8, 2026
completion
Sep 8, 2026
last updated
Jul 1, 2026
official title
An Open-Label, Phase 1, Single Dose, Randomized, Parallel-group Study to Evaluate the Relative Bioavailability of Two Evolocumab (AMG 145) Drug Products
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol